STEIDL, CAROLINA
STEIDL, CAROLINA
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies
2024 Malighetti, F; Villa, M; Mauri, M; Piane, S; Crippa, V; Crespiatico, I; Cocito, F; Bossi, E; Steidl, C; Civettini, I; Scollo, C; Ramazzotti, D; Gambacorti-Passerini, C; Piazza, R; Mologni, L; Aroldi, A
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia
2023 Aroldi, A; Mauri, M; Ramazzotti, D; Villa, M; Malighetti, F; Crippa, V; Cocito, F; Borella, C; Bossi, E; Steidl, C; Scollo, C; Voena, C; Chiarle, R; Mologni, L; Piazza, R; Gambacorti Passerini, C
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience
2022 Steidl, C; Aroldi, A; Mologni, L; Crespiatico, I; Fontana, D; Mastini, C; Fumagalli, M; Perfetti, P; Borin, L; Valentini, C; Piazza, R; Gambacorti-Passerini, C
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy
2020 Bossi, E; Aroldi, A; Brioschi, F; Steidl, C; Baretta, S; Renso, R; Verga, L; Fontana, D; Sharma, G; Mologni, L; Mussolin, L; Piazza, R; Gambacorti Passerini, C
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy
2019 Bossi, E; Brioschi, F; Steidl, C; Baretta, S; Cantu, S; Verga, L; Fontana, D; Sharma, G; Mologni, L; Mussolin, L; Piazza, R; Gambacorti Passerini, C